Commission Briefing Package: Petition to Exempt Baloxavir Marboxil (XOFLUZA) in 40 mg and 80 mg Tablet Doses from Special Packaging Requirements of the PPPA

Attachment

Petition-to-Exempt-Baloxavir-Marboxil-XOFLUZA-in-40-mg-and-80-mg-Tablet-Doses-from-Special-Packaging-Requirements-of-the-PPPA-Cleared-003-Redacted.pdf (1.45 MB)

Type

Commission Briefing Packages

Date

Tuesday, September 21, 2021 - 11:42

Report an unsafe product